Influence of intensity-modulated radiotherapy (IMRT) on xerostomia, salivary pH, and quality of life in patients with tumors of the oral cavity and pharynx (pre- and post-IMRT).

Influence of intensity-modulated radiotherapy (IMRT) on xerostomia, salivary pH, and quality of life in patients with tumors of the oral cavity and pharynx (pre- and post-IMRT). - IMRT saliva

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00037661

Enrollment

Registered

2025-08-11

Start date

2025-08-01

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C10

Interventions

Group 1: In patients receiving radiotherapy in the head and neck region, salivary flow rate, salivary pH, and questionnaires (oral health, salivary flow rate) are measured at T0, T1, T2, and T3.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with oropharyngeal tumors (ICD C00–C10, C14) undergoing IMRT.

Exclusion criteria

Exclusion criteria: Lack of patient consent; Patients with dementia or other cognitive impairments who are unable to provide informed consent; Patients who decline participation in the study for other reasons

Design outcomes

Primary

Measure	Time frame
Salivary flow rate, salivary pH, and questionnaires (VAS, Xerostomia Inventory, EORTC QLQ-C30) are assessed before IMRT (T0), after IMRT (T1), 3 months post-IMRT (T2), and 12 months post-IMRT (T3).	—

Secondary

Measure	Time frame
Submandibular, Sublingual, and Parotid Glands: Preserved or Resected, Radiation dose (Gy), Surgical report: Resection, Patient record: Medication list, Demographic data	—

Countries

Germany

Contacts

Public ContactSabine Linsen

UKB Poliklinik für Zahnärztliche Prothetik

sabine.linsen@ukbonn.de+4922828722436

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026